Compare VRRM & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRRM | HROW |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2016 | 2008 |
| Metric | VRRM | HROW |
|---|---|---|
| Price | $4.72 | $40.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $25.90 | ★ $69.86 |
| AVG Volume (30 Days) | ★ 5.2M | 583.5K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 347.37 | 71.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $132,969,000.00 | N/A |
| Revenue This Year | $6.84 | $31.62 |
| Revenue Next Year | $6.88 | $50.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.61 | N/A |
| 52 Week Low | $3.40 | $28.54 |
| 52 Week High | $25.57 | $54.98 |
| Indicator | VRRM | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 48.17 |
| Support Level | $4.02 | $37.03 |
| Resistance Level | $4.75 | $41.82 |
| Average True Range (ATR) | 0.30 | 1.94 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 32.44 | 52.97 |
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe, and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three reportable segments: Commercial Services, Government Solutions, and Parking Solutions. Maximum revenue is generated from the Commercial Services segment, which offers toll and violation management solutions and title and registration services for commercial fleet customers, including RACs and FMCs in North America. In Europe, it provides tolling and violations processing services.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.